

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 63592

**Title:** Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

**Reviewer's code:** 03664527

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-02-19 05:19

**Reviewer performed review:** 2021-02-19 11:06

**Review time:** 5 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ☐ ] Yes [ ☒ ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

As early as 2011, the author proposed a novel nanosome SapC-DOPS . This substance can inhibit the proliferation of tumor cells and enhance the toxicity of gemcitabine, but the effect in vivo is not clear, and additional in vivo tests are needed.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 63592

**Title:** Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

**Reviewer's code:** 05106105

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Chief Technician, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-02-18 10:01

**Reviewer performed review:** 2021-02-21 03:17

**Review time:** 2 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

Comments to the Author In your review, you describe the mechanisms and efficacy of SapC-DOPS, a novel phosphatidylserine (PS) biomarker targeted nanodrug, alone and in combination with other treatment modalities such as gemcitabine (GEM), Abraxane and radiation for the treatment of pancreatic ductal adenocarcinoma (PDAC) tumors in vivo, which has not been reviewed in the literature. Your reference documentation is very comprehensive and the review concludes almost all conditions that may have something to do with SapC-DOPS. I can imagine how much work you have done for this professional review. I recommend that you give a final polish to your writing to keep your message as concise as possible. For example, there's too much in the introduction and current therapy sections. I really appreciate your great work and it's my great honor to read this paper.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 63592

**Title:** Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

**Reviewer's code:** 03821481

**Position:** Peer Reviewer

**Academic degree:** MD, MSc

**Professional title:** Attending Doctor, Doctor, Instructor, Surgeon

**Reviewer's Country/Territory:** Portugal

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-02-18 08:53

**Reviewer performed review:** 2021-03-17 19:04

**Review time:** 27 Days and 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear author, Very interesting and well written review. It clearly demonstrates possible benefits of SapS-DPOS not only from a therapeutic stand point but also as a possible imaging agent. Its synergist effect with current chemotherapy agents and even in combination with radiation on tumor cells makes this a drug a very promising new addition to currently available medications. I would like to know if there are any studies regarding combination with mFOLFIRINOX as it is first line treatment in fit patients. As you say in your introduction gemcitabine is a first line drug but not "generally the first line", particularly in monotherapy. Also, please review Table 1 as per AJCC 8th edition (please refer to attachment). Congratulations.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 63592

**Title:** Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer

**Reviewer's code:** 03821481

**Position:** Peer Reviewer

**Academic degree:** MD, MSc

**Professional title:** Attending Doctor, Doctor, Instructor, Surgeon

**Reviewer's Country/Territory:** Portugal

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-29

**Reviewer chosen by:** Chen-Chen Gao

**Reviewer accepted review:** 2021-04-14 05:21

**Reviewer performed review:** 2021-04-17 15:07

**Review time:** 3 Days and 9 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

Thank you for the changes. You can find attached a suggestion for the AJCC prognostic groups as there are still some minor details that are not in accordance with the 8th edition. Congratulations.